Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema.

Nasser G AlsaediRuba M AlselaimyAbdulaziz A AlshamraniMuhammed AlAjmiRajiv KhandekarHassan Al-DhibiAbdulelah A Al-Abdullah

Published in: Clinical ophthalmology (Auckland, N.Z.) (2021)

After treating refractory DME with initial bevacizumab injections, 3 injections of either aflibercept or ranibizumab had similar anatomic and functional outcomes. Aflibercept achieved dry macula in more eyes with refractory DME compared to ranibizumab.

Keyphrases

age related macular degeneration
metastatic colorectal cancer
platelet rich plasma
ultrasound guided
optical coherence tomography
diabetic retinopathy
stem cells
bone marrow